©The Author(s) 2025.
World J Clin Oncol. Oct 24, 2025; 16(10): 110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511
Table 3 Pooled event rates for clinical endpoints (%)
| Endpoint | Pooled % | 95%CI | I² | P value |
| MPR | 19 | 13-25 | 0.0 | 0.77 |
| ORR | 35 | 18-52 | 84.1 | < 0.001 |
| pCR | 22 | 10-34 | 85.5 | < 0.001 |
| Resection rate | 81 | 72-91 | 75.9 | < 0.001 |
| Grade 3-4 TRAEs | 19 | 11-26 | 34.2 | 0.16 |
- Citation: Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511
- URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110511